Objective Patients with acute myelogenous leukemia or myelodysplastic syndrome
undergoing induction chemotherapy are at increased risk of invasive fungal infection due to
prolonged, severe neutropenia. Due to this risk, national guidelines recommend invasive
fungal infection prophylaxis in this population until the resolution of neutropenia. Although
posaconazole has demonstrated superiority over fluconazole and itraconazole, there is
limited evidence for voriconazole for invasive fungal infection prophylaxis in this population …